Cancer treatment and survivorship statistics, 2016

CA Cancer Journal for Clinicians

Volumn 66, Issue 4, 2016, Pages 271-289

  Miller, Kimberly D ^a   Siegel, Rebecca L ^a   Lin, Chun Chieh ^a   Mariotto, Angela B ^b   Kramer, Joan L ^c   Rowland, Julia H ^b   Stein, Kevin D ^d   Alteri, Rick ^a   Jemal, Ahmedin ^a  

^a AMERICAN CANCER SOCIETY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BEHAVIORAL RESEARCH CENTER   (United States)

Author keywords

prevalence; statistics; survivorship; treatment patterns

Indexed keywords

ANTHRACYCLINE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; B RAF KINASE INHIBITOR; BCG VACCINE; HORMONE; IODINE 131; IPILIMUMAB; NIVOLUMAB; OXALIPLATIN; PEMBROLIZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; TAMOXIFEN; TAXANE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; AGE DISTRIBUTION; AGING; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTHRALGIA; ARTICLE; ATROPHIC VAGINITIS; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; BLADDER CANCER; BREAST CANCER; BREAST RECONSTRUCTION; CANCER GRADING; CANCER REGISTRY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CANCER THERAPY; CARDIOMYOPATHY; CHILDHOOD CANCER; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CHRONIC PAIN; COLON CANCER; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; DISEASE DURATION; DYSPAREUNIA; EARLY DIAGNOSIS; EARLY MENOPAUSE; EVIDENCE BASED MEDICINE; GERM CELL TUMOR; HEALTH CARE QUALITY; HODGKIN DISEASE; HOT FLUSH; HUMAN; HYSTERECTOMY; INFERTILITY; LUNG CANCER; LYMPH NODE DISSECTION; LYMPHEDEMA; MALE SEXUAL DYSFUNCTION; MASTECTOMY; MEDICAL HISTORY; MELANOMA; MENOPAUSAL SYNDROME; MYALGIA; NEUROPATHY; NIGHT SWEAT; NONHODGKIN LYMPHOMA; OSTEOPOROSIS; OVERALL SURVIVAL; POPULATION GROWTH; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PSYCHOLOGICAL WELL BEING; PSYCHOSOCIAL CARE; PUBLIC HEALTH; QUALITY OF LIFE; RECTUM CANCER; SALPINGOOOPHORECTOMY; SENTINEL LYMPH NODE BIOPSY; SPLENECTOMY; SURVIVAL TIME; T CELL LYMPHOMA; THYROID CANCER; THYROIDECTOMY; TRANSURETHRAL RESECTION; UTERUS CANCER; ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; CHILD; COLONIC NEOPLASMS; FEMALE; INCIDENCE; INFANT; MALE; MIDDLE AGED; MORTALITY; NATIONAL HEALTH ORGANIZATION; NEOPLASMS; NEWBORN; NON PROFIT ORGANIZATION; PRESCHOOL CHILD; PROSTATIC NEOPLASMS; REGISTER; RISK FACTOR; SKIN NEOPLASMS; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; SURVIVOR; UNITED STATES; UTERINE NEOPLASMS; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMERICAN CANCER SOCIETY; BREAST NEOPLASMS; CHILD; CHILD, PRESCHOOL; COLONIC NEOPLASMS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MELANOMA; MIDDLE AGED; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; PREVALENCE; PROSTATIC NEOPLASMS; REGISTRIES; RISK FACTORS; SKIN NEOPLASMS; SURVIVAL RATE; SURVIVORS; UNITED STATES; UTERINE NEOPLASMS;

EID: 84973649618     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21349     Document Type: Article

References (138)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7-30.
2. Weaver KE, Forsythe LP, Reeve BB, et al. Mental and physical health-related quality of life among US cancer survivors: population estimates from the 2010 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 2012;21:2108-2117.
3. Verdecchia A, De Angelis G, Capocaccia R. Estimation and projections of cancer prevalence from cancer registry data. Stat Med. 2002;21:3511-3526.
4. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252-271.
5. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220-241.
6. Mariotto AB, Yabroff KR, Feuer EJ, De Angelis R, Brown M. Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000-2020. Cancer Causes Control. 2006;17:1215-1226.
7. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103:117-128.
8. Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
9. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.
10. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2012. seer.cancer.gov/csr/1975_2012/ (based on November 2014 SEER data submission). Bethesda, MD: National Cancer Institute, 2015.
11. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2014 Sub (1973-2012 varying)-Linked To County Attributes-Total US, 1969–2013 Counties. Bethesda, MD: National Cancer Institute, Department of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2015.
12. Surveillance Research Program, National Cancer Institute. SEER*Stat software, version 8.2.1. Bethesda, MD: National Cancer Institute; 2015.
13. Lerro CC, Robbins AS, Phillips JL, Stewart AK. Comparison of cases captured in the national cancer data base with those in population-based central cancer registries. Ann Surg Oncol. 2013;20:1759-1765.
14. American College of Surgeons, Commission on Cancer. National Cancer Database, 2013 Data Submission. Chicago, IL: American College of Surgeons; 2015.
15. Fedewa SA, Ward EM, Stewart AK, Edge SB. Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: a national cohort study 2004-2006. J Clin Oncol. 2010;28:4135-4141.
16. Bhargava A, Du XL. Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph node-positive, operable breast cancer. Cancer. 2009;115:2999-3008.
17. Jatoi I, Proschan MA. Randomized trials of breast-conserving therapy versus mastectomy for primary breast cancer: a pooled analysis of updated results. Am J Clin Oncol. 2005;28:289-294.
18. Litiere S, Werutsky G, Fentiman IS, et al. Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol. 2012;13:412-419.
19. McGuire KP, Santillan AA, Kaur P, et al. Are mastectomies on the rise? A 13-year trend analysis of the selection of mastectomy versus breast conservation therapy in 5865 patients. Ann Surg Oncol. 2009;16:2682-2690.
20. Freedman RA, Virgo KS, Labadie J, He Y, Partridge AH, Keating NL. Receipt of locoregional therapy among young women with breast cancer. Breast Cancer Res Treat. 2012;135:893-906.
21. Kummerow KL, Du L, Penson DF, Shyr Y, Hooks MA. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg. 2015;150:9-16.
22. Freedman RA, Kouri EM, West DW, et al. Higher stage of disease is associated with bilateral mastectomy among patients with breast cancer: a population-based survey. Clin Breast Cancer. 2016;16:105-112.
23. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784-1792.
24. Vona-Davis L, Rose DP. The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. J Womens Health (Larchmt). 2009;18:883-893.
25. Danforth DN Jr. Disparities in breast cancer outcomes between Caucasian and African American women: a model for describing the relationship of biological and nonbiological factors [serial online]. Breast Cancer Res. 2013;15:208.
26. Curtis E, Quale C, Haggstrom D, Smith-Bindman R. Racial and ethnic differences in breast cancer survival: how much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? Cancer. 2008;112:171-180.
27. DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013;14:500-515.
28. Lawenda BD, Mondry TE, Johnstone PA. Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA Cancer J Clin. 2009;59:8-24.
29. Shaitelman SF, Cromwell KD, Rasmussen JC, et al. Recent progress in the treatment and prevention of cancer-related lymphedema. CA Cancer J Clin. 2015;65:55-81.
30. Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol. 2016;34:611-635.
31. Gartner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA. 2009;302:1985-1992.
32. Vilholm OJ, Cold S, Rasmussen L, Sindrup SH. The postmastectomy pain syndrome: an epidemiological study on the prevalence of chronic pain after surgery for breast cancer. Br J Cancer. 2008;99:604-610.
33. Steegers MA, Wolters B, Evers AW, Strobbe L, Wilder-Smith OH. Effect of axillary lymph node dissection on prevalence and intensity of chronic and phantom pain after breast cancer surgery. J Pain. 2008;9:813-822.
34. Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104:386-405.
35. Rivera E, Cianfrocca M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol. 2015;75:659-670.
36. Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23(suppl 7):vii155-vii166.
37. Conte P, Frassoldati A. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: putting safety issues into perspective. Breast J. 2007;13:28-35.
38. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771-784.
39. Schover LR, van der Kaaij M, van Dorst E, Creutzberg C, Huyghe E, Kiserud CE. Sexual dysfunction and infertility as late effects of cancer treatment. EJC Suppl. 2014;12:41-53.
40. Pinto AC, de Azambuja E. Improving quality of life after breast cancer: dealing with symptoms. Maturitas. 2011;70:343-348.
41. Boissel N, Sender LS. Best practices in adolescent and young adult patients with acute lymphoblastic leukemia: a focus on asparaginase. J Adolesc Young Adult Oncol. 2015;4:118-128.
42. Parsons HM, Harlan LC, Seibel NL, Stevens JL, Keegan TH. Clinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference? J Clin Oncol. 2011;29:4045-4053.
43. Bleyer A. Young adult oncology: the patients and their survival challenges. CA Cancer J Clin. 2007;57:242-255.
44. Albritton K, Barr R, Bleyer A. The adolescence of young adult oncology. Semin Oncol. 2009;36:478-488.
45. Armstrong GT, Oeffinger KC, Chen Y, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol. 2013;31:3673-3680.
46. Hudson MM, Ness KK, Gurney JG, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013;309:2371-2381.
47. Castellino SM, Ullrich NJ, Whelen MJ, Lange BJ. Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors [serial online]. J Natl Cancer Inst. 2014;106. pii:dju186.
48. Barton SE, Najita JS, Ginsburg ES, et al. Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2013;14:873-881.
49. Wasilewski-Masker K, Seidel KD, Leisenring W, et al. Male infertility in long-term survivors of pediatric cancer: a report from the Childhood Cancer Survivor Study. J Cancer Surviv. 2014;8:437-447.
50. Barr RD, Ferrari A, Ries L, Whelan J, Bleyer WA. Cancer in adolescents and young adults: a narrative review of the current status and a view of the future [published online ahead of print March 21, 2016]. JAMA Pediatr. doi: 10.1002/jamapediatrics.2015.4689.
51. Surveillance, Epidemiology, and End Results (SEER) Program. SEER-Medicare linked database 2006–2010. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Applied Research Program, Health Services and Economics Branch; 2013.
52. Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol. 2002;29:21-33.
53. Ramsey SD, Berry K, Moinpour C, Giedzinska A, Andersen MR. Quality of life in long term survivors of colorectal cancer. Am J Gastroenterol. 2002;97:1228-1234.
54. Emmertsen KJ, Laurberg S; Rectal Cancer Function Study Group. Impact of bowel dysfunction on quality of life after sphincter-preserving resection for rectal cancer. Br J Surg. 2013;100:1377-1387.
55. Lange MM, Martz JE, Ramdeen B, et al. Long-term results of rectal cancer surgery with a systematical operative approach. Ann Surg Oncol. 2013;20:1806-1815.
56. Den Oudsten BL, Traa MJ, Thong MS, et al. Higher prevalence of sexual dysfunction in colon and rectal cancer survivors compared with the normative population: a population-based study. Eur J Cancer. 2012;48:3161-3170.
57. Liu L, Herrinton LJ, Hornbrook MC, Wendel CS, Grant M, Krouse RS. Early and late complications among long-term colorectal cancer survivors with ostomy or anastomosis. Dis Colon Rectum. 2010;53:200-212.
58. El-Shami K, Oeffinger KC, Erb NL, et al. American Cancer Society Colorectal Cancer Survivorship Care Guidelines. CA Cancer J Clin. 2015;65:427-455.
59. Primrose JN, Perera R, Gray A, et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA. 2014;311:263-270.
60. Tjandra JJ, Chan MK. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum. 2007;50:1783-1799.
61. Mariotto AB, Rowland JH, Ries LA, Scoppa S, Feuer EJ. Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev. 2007;16:566-571.
62. Surveillance, Epidemiology and End Results (SEER) Program. SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence-CiNA Analytic File, 1995–2012, for NHIAv2 Origin, Custom File With County, ACS Facts & Figures Projection Project, NAACCR. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; 2015.
63. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453-474.
64. Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136-1152.
65. Ferdinand R, Mitchell SA, Batson S, Tumur I. Treatments for chronic myeloid leukemia: a qualitative systematic review. J Blood Med. 2012;3:51-76.
66. Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer. 2003;98:1337-1354.
67. Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109:3189-3197.
68. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013;381:1943-1955.
69. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425-2437.
70. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370:1101-1110.
71. Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015;385:1873-1883.
72. Jain P, O'Brien S. Richter's transformation in chronic lymphocytic leukemia. Oncology (Williston Park). 2012;26:1146-1152.
73. Tsai HK, Mauch PM. Nodular lymphocyte-predominant Hodgkin lymphoma. Semin Radiat Oncol. 2007;17:184-189.
74. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998;339:21-26.
75. Coiffier B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol. 2005;23:6387-6393.
76. Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2012;380:848-857.
77. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371:1030-1043.
78. Poghosyan H, Sheldon LK, Leveille SG, Cooley ME. Health-related quality of life after surgical treatment in patients with non-small cell lung cancer: a systematic review. Lung Cancer. 2013;81:11-26.
79. Chambers SK, Dunn J, Occhipinti S, et al. A systematic review of the impact of stigma and nihilism on lung cancer outcomes [serial online]. BMC Cancer. 2012;12:184.
80. Karam-Hage M, Cinciripini PM, Gritz ER. Tobacco use and cessation for cancer survivors: an overview for clinicians. CA Cancer J Clin. 2014;64:272-290.
81. Sitas F, Weber MF, Egger S, Yap S, Chiew M, O'Connell D. Smoking cessation after cancer. J Clin Oncol. 2014;32:3593-3595.
82. Karimkhani C, Gonzalez R, Dellavalle RP. A review of novel therapies for melanoma. Am J Clin Dermatol. 2014;15:323-337.
83. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23-34.
84. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521-2532.
85. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
86. Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol. 2013;14:e60-69.
87. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
88. Balamurugan A, Rees JR, Kosary C, Rim SH, Li J, Stewart SL. Subsequent primary cancers among men and women with in situ and invasive melanoma of the skin. J Am Acad Dermatol. 2011;65:S69-S77.
89. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
90. Smith RA, Andrews K, Brooks D, et al. Cancer screening in the United States, 2016: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2016;66:95-114.
91. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293:2095-2101.
92. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009;302:1202-1209.
93. Shappley WV 3rd, Kenfield SA, Kasperzyk JL, et al. Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol. 2009;27:4980-4985.
94. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138-148.
95. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995-2005.
96. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424-433.
97. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187-1197.
98. Birkhahn M, Penson DF, Cai J, et al. Long-term outcome in patients with a Gleason score ≤ 6 prostate cancer treated by radical prostatectomy. BJU Int. 2011;108:660-664.
99. Nam RK, Cheung P, Herschorn S, et al. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. Lancet Oncol. 2014;15:223-231.
100. Alicikus ZA, Yamada Y, Zhang Z, et al. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer. 2011;117:1429-1437.
101. Resnick MJ, Koyama T, Fan KH, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368:436-445.
102. Taylor KL, Luta G, Miller AB, et al. Long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial. J Clin Oncol. 2012;30:2768-2775.
103. Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol. 2009;27:3452-3458.
104. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2013;189:S34-S42; discussion S43–S34.
105. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102:39-46.
106. Wadhwa VK, Weston R, Mistry R, Parr NJ. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int. 2009;104:800-805.
107. Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306:2359-2366.
108. Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010;60:194-201.
109. Skolarus TA, Wolf AM, Erb NL, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin. 2014;64:225-249.
110. Leung E, Warde P, Jewett M, et al. Treatment burden in stage I seminoma: a comparison of surveillance and adjuvant radiation therapy. BJU Int. 2013;112:1088-1095.
111. Willemse PM, Burggraaf J, Hamdy NA, et al. Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors. Br J Cancer. 2013;109:60-67.
112. Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends-An Update. Cancer Epidemiol Biomarkers Prev. 2016;25:16-27.
113. Davies L, Morris LG, Haymart M, et al. American Association of Clinical Endocrinologists and American College of Endocrinology disease state clinical review: the increasing incidence of thyroid cancer. Endocr Pract. 2015;21:686-696.
114. Morris LG, Tuttle RM, Davies L. Changing trends in the incidence of thyroid cancer in the United States. JAMA Otolaryngol Head Neck Surg. 2016 April 14; [Epub ahead of print].
115. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009;115:3801-3807.
116. Schmid D, Ricci C, Behrens G, Leitzmann MF. Adiposity and risk of thyroid cancer: a systematic review and meta-analysis. Obes Rev. 2015;16:1042-1054.
117. Pitt SC, Moley JF. Medullary, anaplastic, and metastatic cancers of the thyroid. Semin Oncol. 2010;37:567-579.
118. Haymart MR, Banerjee M, Stewart AK, Koenig RJ, Birkmeyer JD, Griggs JJ. Use of radioactive iodine for thyroid cancer. JAMA. 2011;306:721-728.
119. Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 2011;117:4439-4446.
120. Santoro M, Carlomagno F. Central role of RET in thyroid cancer [serial online]. Cold Spring Harb Perspect Biol. 2013;5:a009233.
121. Cheung G, Sahai A, Billia M, Dasgupta P, Khan MS. Recent advances in the diagnosis and treatment of bladder cancer [serial online]. BMC Med. 2013;11:13.
122. Efstathiou JA, Spiegel DY, Shipley WU, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012;61:705-711.
123. Mitin T, Hunt D, Shipley WU, et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol. 2013;14:863-872.
124. Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol. 1983;130:1083-1086.
125. Lutzeyer W, Rubben H, Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol. 1982;127:250-252.
126. Lee RK, Abol-Enein H, Artibani W, et al. Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. BJU Int. 2014;113:11-23.
127. Roghmann F, Becker A, Trinh QD, et al. Updated assessment of neobladder utilization and morbidity according to urinary diversion after radical cystectomy: a contemporary US-population-based cohort. Can Urol Assoc J. 2013;7:E552-E560.
128. Audette C, Waterman J. The sexual health of women after gynecologic malignancy. J Midwifery Womens Health. 2010;55:357-362.
129. Tada H, Teramukai S, Fukushima M, Sasaki H. Risk factors for lower limb lymphedema after lymph node dissection in patients with ovarian and uterine carcinoma [serial online]. BMC Cancer. 2009;9:47.
130. Kent EE, Ambs A, Mitchell SA, Clauser SB, Smith AW, Hays RD. Health-related quality of life in older adult survivors of selected cancers: data from the SEER-MHOS linkage. Cancer. 2015;121:758-765.
131. Koch L, Jansen L, Brenner H, Arndt V. Fear of recurrence and disease progression in long-term (≥5 years) cancer survivors—a systematic review of quantitative studies. Psychooncology. 2013;22:1-11.
132. Kim Y, Kashy DA, Spillers RL, Evans TV. Needs assessment of family caregivers of cancer survivors: three cohorts comparison. Psychooncology. 2010;19:573-582.
133. Demark-Wahnefried W, Rogers LQ, Alfano CM, et al. Practical clinical interventions for diet, physical activity, and weight control in cancer survivors. CA Cancer J Clin. 2015;65:167-189.
134. Westmaas JL, Alcaraz KI, Berg CJ, Stein KD. Prevalence and correlates of smoking and cessation-related behavior among survivors of ten cancers: findings from a nationwide survey nine years after diagnosis. Cancer Epidemiol Biomarkers Prev. 2014;23:1783-1792.
135. National Cancer Institute, National Institutes of Health, US Department of Health and Human Services. Cancer Trends Progress Report. Bethesda, MD: National Cancer Institute, National Institutes of Health, US Department of Health and Human Services; 2015. progressreport.cancer.gov. Accessed January 6, 2016.
136. American College of Surgeons. Cancer program standards 2016: ensuring patient-centered care. facs.org/quality%20programs/cancer/coc/standards. Accessed December 30, 2015.
137. Alliance for Quality Psychosocial Cancer Care. A Resource Guide for CoC-Accredited Facilities: Meeting the Commission on Cancer Patient-Centered Standards. cfah.org/pdfs/Alliance_Resource_Guide_for_CoC_Patient_Centered_Standards_February2015.pdf. Accessed December 30, 2015.
138. Cohen EEW, LaMonte SJ, Erb NL, et al. American Cancer Society head and neck cancer survivorship care guideline [published online ahead of print March 22, 2016]. CA Cancer J Clin. doi: 10.3322/caac.21343.